- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02394249
SIT LESS 3: The Effect of Low Intensity Physical Activity on Insulin Sensitivity, Mood and Cognitive Performance (SIT LESS 3)
Background of the study:
A sedentary lifestyle and obesity are well known risk factors of type 2 diabetes. The major focus of current guidelines for type 2 diabetes prevention is on energy balance. Physical activity guidelines recommend at least 30 minutes/day of moderate to vigorous physical activity (MVPA). However, no advice is given how the other 23.5 hours of the day should be spent. Several recent epidemiologic studies suggest that excessive sitting, independent of moderate to vigorous physical activity, has detrimental health effects. Another possibility to sit less is by increasing low intensity physical activities as slowly walking and standing. A recent published study of Duvivier and colleagues suggests that sitting less and replacing it by slowly walking and standing has a better effect on insulin action and cardiovascular risk factors than the combination of one hour MVPA per day and sitting the rest of the day in healthy subjects (Duvivier et al. PLOS ONE 2013). Until now this research is not performed in subjects with overweight/obesity.
Objective of the study:
To assess the effect of low intensity physical activity on plasma insulin levels, cognition and mood in subjects with overweight/obesity
Study population:
21 subjects between 40-80 years old with overweight/obesity
Intervention:
2 activity regimes of 4 days: a sitting regime and a "sit less" regime
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Maastricht, Netherlands, 6200MD
- Human Movement Science, Maastricht University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- Men and postmenopausal women: 40-80 years old
- BMI: 25.0 - 35.0 kg/m2
- Maximum 2.5 hours of MVPA per week (during last 3 months)
- Having a general practitioner
- Agreeing to be informed about medically relevant personal test-results by a physician
- Accessible veins on arms as determined by examination at screening
Exclusion Criteria:
- Reported participation in another biomedical trial which may have an effect on insulin sensitivity one month before the pre-study examination or during the study
- Blood donation in the past three months
- Reported participation in night shift work 2 weeks prior to pre-study investigation or during the study. Night work is defined as working between midnight and 6.00 AM.
- Consumption of >14 (women) or > 21 (men) alcoholic units per week
- Reported dietary habits: medically prescribed diet, slimming diet;
- Reported weight loss (>2kg) in the last three months prior to the screening;
- Not being able to execute at least three (out of four) cognition tests in the training session
- Not being able to execute the sit less try-out day
- Being an employee of Unilever or the collaborating research departments in Maastricht University Medical Centre
- Experimental drug use (during the last 3 months)
- Use of insulin, oral blood glucose lowering medication (metformin and/or SU-derivatives and/or DPP-IV inhibitors), corticosteroids or vitamin K antagonists in the last 3 months
- Fasting plasma glucose level > 6.9 mmol/L
- Medical conditions which make participation in the study not responsible which will be decided by a medical doctor during screening
- Other clinically relevant abnormalities in clinical chemistry at screening (to be judged by a medical doctor)
- Mental or physical disability which interferes with physical activity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sitting regime
The subjects will follow the sitting regime during four days.
Each day: 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
|
Information already included in arm descriptions
|
Experimental: Sit Less regime
Subjects will follow the sit less regime during four days.
Each day will consist of 9 hours sitting, 4 hours walking, 3 hours standing and 8 hours sleeping.
The walking and standing will be done in a minimum of eight bouts with a time interval of >1 hour.
The subjects will be instructed to walk on a slow pace, i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
|
Information already included in arm descriptions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma insulin levels (measured as area under the curve during an oral glucose tolerance test)
Time Frame: one day after each regime
|
To assess the effect of low intensity physical activity (LIPA) on plasma insulin levels (as measured as area under the curve during an oral glucose tolerance test)
|
one day after each regime
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin sensitivity (measured as Matsuda combined insulin sensitivity index during an oral glucose tolerance test)
Time Frame: one day after each regime
|
To assess the effect of LIPA on insulin sensitivity
|
one day after each regime
|
Plasma C-peptide
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma C-peptide
|
one day after each regime
|
Plasma glucose levels
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma glucose levels
|
one day after each regime
|
Plasma triglycerides
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma triglycerides
|
one day after each regime
|
Plasma total cholesterol
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma total cholesterol
|
one day after each regime
|
Plasma non-HDL cholesterol
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma non-HDL cholesterol
|
one day after each regime
|
Plasma HDL cholesterol
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma HDL cholesterol
|
one day after each regime
|
Plasma LDL cholesterol
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma LDL cholesterol
|
one day after each regime
|
Plasma free fatty acids
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma free fatty acids
|
one day after each regime
|
Plasma apolipoprotein B
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma apolipoprotein B
|
one day after each regime
|
Plasma apolipoprotein A
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma apolipoprotein A
|
one day after each regime
|
Mood (measured by the Affect Grid mood scale)
Time Frame: 2 days: last day of each regime and one day after each regime
|
To assess the effect of LIPA on mood
|
2 days: last day of each regime and one day after each regime
|
Attention (measured by the Attention Network Task)
Time Frame: one day after each regime before and after the oral glucose tolerance test
|
To assess the effect of LIPA on attention
|
one day after each regime before and after the oral glucose tolerance test
|
Executive Function (measured by the Trail Making Test)
Time Frame: one day after each regime before and after the oral glucose tolerance test
|
To assess the effect of LIPA on executive function
|
one day after each regime before and after the oral glucose tolerance test
|
Memory (measured by the Rey Auditory Verbal Learning Task)
Time Frame: one day after each regime before and after the oral glucose tolerance test
|
To assess the effect of LIPA on memory
|
one day after each regime before and after the oral glucose tolerance test
|
Quality of life (measured by the Gill 32-item questionnaire)
Time Frame: last day of each regime
|
To assess the effect of LIPA on quality of life
|
last day of each regime
|
Sleep (measured by the 10-item Pittsburgh Sleep Quality Index)
Time Frame: last day of each regime
|
To assess the effect of LIPA on sleep
|
last day of each regime
|
Plasma C-reactive protein
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma C-reactive protein
|
one day after each regime
|
Plasma interleukin 1
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma interleukin 1
|
one day after each regime
|
Plasma interleukin 6
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma interleukin 6
|
one day after each regime
|
Plasma TNF-alpha
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma TNF-alpha
|
one day after each regime
|
Plasma interferon gamma
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma interferon gamma
|
one day after each regime
|
Plasma ICAM-1
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma ICAM-1
|
one day after each regime
|
Plasma VCAM
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma VCAM
|
one day after each regime
|
Plasma serum amyloid A (SAA)
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma SAA
|
one day after each regime
|
Plasma E-selectine
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma E-selectine
|
one day after each regime
|
Plasma von Willebrand factor (vWF)
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma vWF
|
one day after each regime
|
Plasma PAI-1
Time Frame: one day after each regime
|
To assess the effect of LIPA on plasma PAI-1
|
one day after each regime
|
To explore the association between plasma glucose, plasma insulin, insulin sensitivity and mood, cognitive performance, quality of life and sleep
Time Frame: one day after each regime
|
one day after each regime
|
|
Blood pressure
Time Frame: one day after each regime
|
one day after each regime
|
|
Heart rate
Time Frame: one day after each regime
|
one day after each regime
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Hans H Savelberg, PhD, Maastricht University Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 143046
- NL50688.068.14 (Registry Identifier: Medical Ethical Committee Maastricht University Hospital / University of Maastricht)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Physical activity regime
-
Hasselt UniversityCompleted
-
Maastricht University Medical CenterDutch Heart FoundationCompletedOverweight and ObesityNetherlands
-
Health Education Research Foundation (HERF)CompletedQuality of LifePakistan
-
Zohra Institute of Health SciencesCompletedPhysical Activity and StressPakistan
-
Centre Hospitalier Universitaire DijonWithdrawn
-
Fundacion para la Investigacion y Formacion en...CompletedImpaired CognitionSpain
-
AUSL Romagna RiminiFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRecruitingNon-Small Cell Lung CancerItaly
-
Fundación para la Investigación del Hospital Clínico...CompletedObesity | Severe Mental Disorder
-
Augusta UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Kansas... and other collaboratorsCompletedMental Disorders, SevereUnited States
-
Centre Hospitalier Departemental VendeeTerminated